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Abstract
Background: The long-term success of coronary artery bypass grafting (CABG) depends on secondary prevention.
Vast evidence provided by the results of cholesterol mega-trials over two decades has shown that effective reduction
of LDL cholesterol improves the prognosis of patients with coronary heart disease. However, the implementation of
these results into the clinical practice has turned out to be challenging. We analysed how the information derived from
clinical statin trials and international recommendations affected the local treatment practices of dyslipidaemia of CABG
patients during a 20-year time period.
Methods: The cohort includes all CABG patients (n = 953) treated in Kanta-Häme Central Hospital during the time
period 1990–2009. At the postoperative visits in the cardiology outpatient clinic, each patient’s statin prescription was
recorded, and blood lipids were determined.
Results: During 1990–1994, 12.0 % of patients were on statins and during the following 5-year time periods the
proportion was 57.2, 82.2 and 96.8 %, respectively. During the 20-year observation period (1990–2009), the effective
statin dose increased progressively during these 5-year periods up to 36-fold, while the mean concentration of LDL
cholesterol decreased from 3.7 to 2.1 mmol/l and that of apolipoprotein B from 1.3 to 0.8 g/l. In the very last year
of follow-up, the mean concentrations of LDL-C and apoB were 1.83 mmol/l and 0.78 g/l, respectively. The most
prominent increase in statin use and dosage took place during 1994–1996 and 2003–2005, respectively.
Conclusions: Among CABG patients the lipid-lowering efficacy of statin therapy improved dramatically since
1994. This progress was accompanied by significant and favourable changes of lipid and apolipoprotein-B
values. This study shows that it is possible to effectively improve lipid treatment policy once the results of
relevant trials are available, and that this may happen even before international or national guidelines have
been updated.
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Background
Coronary artery bypass grafting (CABG) efficiently alle-
viates coronary heart disease (CHD) symptoms. How-
ever, without an effective secondary prevention, it does
not offer permanent improvement of cardiac symptoms
or prognosis [1, 2].
The primary target of the secondary prevention of cor-
onary heart disease is effective reduction of low-density
lipoprotein cholesterol (LDL-C), which diminishes car-
diovascular and total mortality [3–6]. The lipid-lowering
therapy is based on two approaches, i.e. change in life-
style and pharmacological therapy [7]. In acute coronary
syndrome patients it is desirable to start an effective
statin therapy immediately after the event, i.e. already
during the hospital stay [8].
According to early mega-trials, the turning points in
secondary prevention of coronary heart disease were the
years 1994, 1996 and 1997 when the first statin mega-
trials 4S and CARE as well as the Post-CABG trial were
published, and showed that effective therapy with statins
improves the prognosis of patients with CHD [2–4]. The
next key observations with a major influence on statin
therapy occurred in 2004–2005, when the beneficial effects
of intensive statin therapy, as compared with moderate
statin therapy, were published [6, 8].
Two lipid-lowering recommendations, one in the U.S.
and the other in Europe, were published just before the
first statin mega-trials, i.e. in 1994 [9, 10]. They pointed
out the central importance of increased cholesterol con-
centrations in determining the CHD risk; yet, due to the
lack of evidence, the recommendations were conservative
in their drug therapy guidelines [9, 10].
In 1998, the European targets for total cholesterol (T-C)
and LDL-C were set below 5.0 mmol/l and 3.0 mmol/l, re-
spectively [11]. One year later in the USA, the target for
LDL-C in CABG patients was set below 100 mg/dL
(2.6 mmol/l) [12]. Further in 2001 and 2003 LDL-C tar-
gets were set below 2.6 mmol/l and 2.5 mmol/l in the
USA and Europe, respectively [13, 14]. Even though the
goals were more demanding, the major emphasis was still
on therapeutic lifestyle changes. Eventually, in 2004 the
American guidelines and in 2007 the European guidelines
for cardiovascular disease prevention recommended that
in patients with established coronary heart disease LDL-C
should be lowered below 2.5 mmol/l, or below 1.8/
2.0 mmol/l, “if achievable” [15, 16].
The evidence indicates that the combined use of differ-
ent apolipoprotein (apo) measures might improve the risk
assessment of cardiovascular disease [17, 18]. Regarding
the atherogenicity of the lipoproteins, the apolipoprotein
B (apoB)-containing lipoproteins are of primary import-
ance. Since one apoB molecule is present in each very-
low-density lipoprotein (VLDL), intermediate-low-density
lipoprotein (IDL) and LDL particle [19, 20], the plasma
concentration of apoB indicates the total number of circu-
lating atherogenic apoB-containing lipoprotein particles.
ApoB concentration as a complementary measure was
included first in recommendations in 2008 [7], and in the
highest risk patients, the treatment goal was set to
0.80 g/l. To achieve this goal, effective lipid-lowering
drug therapy is needed [21].
The aim of our study was to assess whether statin
mega-trials and the recommendations based on their re-
sults influenced the local treatment practice regarding
statin-dependent control of lipid levels in CABG patients
over the critical 20-year period (1990–2009) which
encompassed milestone publications regarding LDL-C
lowering-based pharmacotherapy in preventive cardi-
ology. We also attempted to learn whether the evolving
changes in the LDL-C targets were reflected in the con-
centrations of different lipid classes and apolipoproteins
in the patient cohort.
Methods
Patients
We studied all annual cohorts of CABG patients treated
in Kanta-Häme Central Hospital (K-HCH) during the
years 1990–2009. The primary catchment population of
the hospital is 175 000 inhabitants living in Southern
Finland. CABG was performed in Tampere University
Hospital for 953 patients and, after the operation, they
were transferred to K-HCH for further recovery.
After discharge the patients were followed according
to hospital policy. Of the patients, 946 (99.3 %) had at
least one visit in the outpatient clinic of cardiology during
the first three postoperative months.
Material analysis
Results of all patients who visited the outpatient clinic
were analysed. Patients who had laboratory values on
the first postoperative visit, but not on the 3-month visit,
were also included; that is, a “last observation—carry
forward” principle was adopted. Accordingly, data de-
rived from the final postoperative outpatient visit are
presented, 19 and 81 % of them being derived from the
1 to 3-month visits, respectively.
The year of CABG, postoperative lipid values, medica-
tion, and absence/presence of various CHD risk factors
including smoking, hypertension, diabetes, and obesity
(body mass index, BMI) were collected from the patient
records. Patients’ data were coded, and data analysis was
carried out with the coded material only. The study was
approved by the Ethics Committee of Kanta-Häme
Hospital District (Dnro E511/08).
The influence of the statin trials and recommendations
on treatment goals were examined by comparing CABG
patients’ postoperative lipid values taken at various time
points over a time span of 20 years. The study period
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was divided into four consecutive 5-year time periods,
namely 1990–1994, 1995–1999, 2000–2004, and 2005–
2009. During this 20-year time period several new
statins with different efficacies received their market-
ing authorisation. Accordingly, the daily dose and the
dose-dependent LDL-C lowering effect of each individual
statin had to be taken into account. This enabled us to
compare the lipid-lowering efficacy of the statin therapy
during the entire period.
A daily dose of 20 mg simvastatin or equipotent dose
of another statin is the smallest statin dose used in most
prospective trials, and this dose was defined as “daily
statin dose index (DSDI) 1”. In the Tables and Graphs,
in which the effective doses of various statins are pre-
sented, the DSDI 1 corresponds to a daily dose of 80 mg
fluvastatin, 40 mg lovastatin or pravastatin, 20 mg
simvastatin, 10 mg atorvastatin or 5 mg rosuvastatin.
The lipid-lowering efficacy of each statin was assumed
to be linearly correlated with the dose; i.e. the DSDI of
80 mg simvastatin, 40 mg atorvastatin or 20 mg rosuvas-
tatin was 4 [22–25].
Lipid analysis
Total and high-density lipoprotein cholesterol (HDL-C)
concentrations were determined from plasma samples by
using Hitachi 911 analyser with Boehringer-Mannheim
reagents in 1990–1996. Roche Diagnostics enzymatic
methods were used since 1996, which also applied to direct
LDL-C analysis from 2000 onwards. All chemical analyses
were carried out in the Laboratory of Kanta-Häme Central
Hospital. Lipid analyses have been under the Nordic quality
control during the entire study period.
For the calculation of LDL-C with the classical
Friedewald formula (FW) data on T-C, HDL-C and tri-
glycerides (TG) are required. Since FW is valid provided
serum TG ≤ 4.5 mmol/l, we also applied a novel extended
Friedewald (eFW) approach, which is more tolerant on el-
evated triglycerides [26, 27]. The eFW is based on artificial
neural network regression algorithms which utilize data
on classical FW inputs [26]. This method allowed us to
calculate LDL-C, IDL cholesterol (IDL-C), HDL2 choles-
terol (HDL2-C) and VLDL triglyceride (VLDL-TG) con-
centrations. It also computationally yields estimates of the
apoB and apolipoprotein A-1 (apoA1) concentrations. To
estimate HDL3 cholesterol (HDL3-C), the HDL2-C value
obtained with eFW was subtracted from the measured
HDL-C [26].
Statistical analysis
Evolution of postoperative statin therapy and lipid values
over 20 years was studied using ANOVA test in the 5-year
groups. With dichotomal variables, the 5-year groups were
compared using extended χ2 test [28]. D’Agostino’s test
was used to determine normality and scedasticity. Per-
centage or mean and standard deviation of demographic
characteristics and lipid variables are presented. Multiple
linear regression analysis was used when comparing lipid
values with each other, and also when LDL-C values ob-
tained by enzymatic methods were compared with those
obtained by the classical Friedewald equation or by the ex-
tended Friedewald approach.
Results
Together 400 to 650 CABG patients were operated
yearly in Tampere University Hospital during 1990–
2009. On average, 50 patients of them were postopera-
tively treated annually in K-HCH. Patient records of
altogether 946 subjects who attended postoperative
cardiac outpatient clinic were analysed over a period of
20 years divided into four consecutive 5-year time pe-
riods, each consisting on average of 237 patients (ran-
ging from 219 to 256 patients). The proportion of male
patients ranged from 72 to 80 %. The changes in
patients’ demographics followed both national and inter-
national trends, and the demographic characteristics are
presented in Table 1.
Lipid treatment practice
Altogether 803 patients had their lipid values measured,
81.3 % of them at the 3-month visit. During the first
Table 1 Demographics of patients undergone CABG during 1990–2009, divided into 4 consecutive 5-year periods
5-year period 1990–1994 1995–1999 2000–2004 2005–2009 Overall pa
Number of patients 256 247 224 219 –
Proportion of males (%) 78 80 72 79 0.5193
Proportion of diabetics (%) 10 14 19 27 0.0122
Current and ex-smokers (% 64 55 54 56 0.4544
Age (years) 61.9 ± 7.7 64.0 ± 9.2 65.4 ± 9.4 66.5 ± 8.3 <0.0001
BMI (kg/m2) 26.5 ± 3.5 26.5 ± 3.5 27.2 ± 3.7 27.0 ± 4.1 0.0978
Systolic BP (mmHg) 149.6 ± 24.8 147.9 ± 23.2 137.8 ± 22.0 130.0 ± 20.4 0.0001
Diastolic BP (mmHg) 84.7 ± 11.6 82.1 ± 11.1 80.2 ± 9.8 77.5 ± 9.3 <0.0001
Abbreviations: BMI body mass index (kg/m2), BP blood pressure
aExtended χ2 test and ANOVA were used for overall analysis. Percentage or mean ± standard deviation is presented
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5-year period, 63.6 % of the patients and during the
subsequent 5-year periods 85.6, 94.2 and 96.8 %, re-
spectively, had their lipids analysed. Thus, there was
an initial strong and statistically significant (p < 0.01)
increase in the proportion of patients having their lipids
determined.
During the 20-year observation period, the use of statins
increased markedly, the most prominent increase having
taken place during 1995–1999 (Additional file 1: Table
S1B). Within the last years of the follow-up, practically all
CABG patients were on statin therapy (Fig. 1a).
The DSDIs were small during the initial years, and ef-
fective statin doses increased progressively during the
last years of follow-up. Thus, the average DSDIs of all
patients, even when those without statin therapy were
included, increased during four consecutive 5-year time
periods from 0.07 (±0.23) to 0.46 (±0.53), 1.25 (±1.19)
and 2.52 (±1.52) (p for trend < 0.001) (Fig. 1b, Table 2).
The DSDI 2.86 (±0.41) during the very last year of
observation corresponds to a mean simvastatin dose of
57 (±8) mg/day.
Plasma lipid and apolipoprotein levels
The mean concentrations of LDL-C were 3.7 and
2.1 mmol/l, and those of apoB 1.3 and 0.8 g/l, during the
initial (1990–1994) and final (2005–2009) 5-year time pe-
riods, respectively (Fig. 1, Table 2). During the last single
year of follow-up (2009), the mean concentrations of LDL-
C and apoB were 1.83 mmol/l and 0.78 g/l, respectively.
The decrease in apoB concentration was progressive
during the 20-year time span. It reflects not only the de-
crease in LDL-C concentration, but also in the concen-
trations of other apoB-containing lipoproteins, as seen
in decreases of VLDL-TG and IDL-C, which were re-
duced proportionately (Fig. 2a). HDL-C increased from
1.02 (±0.29) to 1.22 (±0.34) particularly due to an in-
crease in the concentration of HDL2-C, while the con-
centration of HDL3-C remained at a constant level of
0.45 mmol/l (Fig. 2b). The multiple linear correlations of
different lipoproteins are presented in Additional file 2:
Table S2B.
Discussion
Our main findings indicate that during a 20-year follow-
up (1990–2009) of CABG patients the following benefi-
cial changes in lipid and lipoprotein measurements and
in lipid treatment efficacies occurred in sequence. First,
the percentage of patients with measured cholesterol
levels increased, and thereafter, the share of patients on
statin therapy and the efficacy of the therapy increased
consecutively. Moreover, the concentrations of LDL-C
and of apoB, the latter reflecting the number of athero-
genic apoB-containing lipoprotein particles, decreased
by 45 and 40 %, respectively.
Importantly, the primary changes took place immedi-
ately after the first statin mega-trial had been published,
i.e. before their results had been integrated into the
updated formulations of the relevant international guide-
lines [3, 4]. The mean dosage of statin increased rapidly
after 2002, when the most effective statin, rosuvastatin,
had become available in the market. In 2002 and 2005
DSDI-values were 1.08 and 2.56, respectively, see Fig. 1b).
Although during the 20-year follow-up period, the levels
of total cholesterol in the Finnish population steadily
Fig. 1 a LDL-C ± 1 SD calculated by Friedewald formula (mmol/l,
black line ± 1 SD blue shadowing) and the amount of statin users
(%, red line) at postoperative visits. b Plasma correlation of apoB ±
1 SD (g/l, black line ± 1 SD blue shadowing) and daily statin dose
index (DSDI, black line ± 1 SD red shadowing) (see Methods) at
postoperative visits. Red arrows indicate the publication of landmark
studies from left to right: 4S3, CARE4, LIPID5, REVERSAL6 and PROVE IT8.
Blue arrows refer to the publication of lipid lowering recommendations
from left to right: Second European Task Force11, NCEP ATP III12, Third
European Task force13, NCEP ATP III (Implication of recent clinical
trials)14, and Fourth European Task Force15. Black arrows indicate the
years, when the two most effective statins entered the Finnish market,
i.e. atorvastatin in 1997 and rosuvastatin in 2003. LDL-C was calculated
by Friedewald formula and apoB was obtained using extended
Friedewald approach (see Methods)
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decreased [29], the decrease in our patients was 3- to 4-
fold when compared with that of the general population.
This finding accords with the notion that, at least the
majority of the excess decrease in LDL-C among the
CABG patients must have been due to statin treatment.
Thus our results comply with the observed significant
decreases in LDL-C found in mega-trials in which de-
creased cardiovascular morbidity and mortality with in-
tensified statin therapy could also be achieved [3–6, 8].
The efficiency of secondary prevention of CHD in
Europe has been evaluated in the Euroaspire studies I
and II. In the Euroaspire II study (1999–2000) consisting
of coronary patients (including also CABG patients)
from 15 European countries, 42 % had their T-C <
5.0 mmol/l and 61 % were on lipid-lowering medication
[30]. At the same time the corresponding numbers in
our patient population were 68 and 76 %, respectively. In
an international cross-sectional study by Gitt et al. [31],
the prevalence of lipid abnormalities were assessed in
2008–2009 in more than 22 000 European and Canadian
patients on statin treatment. In this study, 58 % of
patients having a cardiovascular high-risk had their
LDL-C < 2.5 mmol/l. Their mean DSDI was 1.85, corre-
sponding to a simvastatin dose of 37 mg [31]. In an-
other study carried out 2009–2010, out of 151 patients
undergone CABG, 83.4 % had lipid profile measured
during the first postoperative year [32]. In this group,
the mean LDL-C level was 1.86 mmol/l, i.e. at the same
level as it was during the last years of our study. It has
recently been indicated, that physicians’ lipid-lowering
treatment choices are usually more conservative than
Table 2 Postoperative plasma lipid and lipoprotein levels in consecutive 5-year periods in statin-treated patients undergone CABG
5-year period 1990–1994 1995–1999 2000–2004 2005–2009 Overall pa
DSDI 0.07 ± 0.23 0.46 ± 0.53 1.25 ± 1.19 2.52 ± 1.52 <0.0001
T-C (mmol/l) 5.70 ± 1.27 4.86 ± 1.00 4.20 ± 0.91 3.76 ± 0.82 <0.0001
LDL-C (mmol/l)b 3.70 ± 1.09 2.94 ± 0.85 2.35 ± 0.72 2.07 ± 0.64 <0.0001
HDL-C (mmol/l) 1.02 ± 0.29 1.12 ± 0.33 1.24 ± 0.32 1.22 ± 0.34 <0.0001
T-G (mmol/l) 2.20 ± 1.22 1.79 ± 0.96 1.56 ± 0.81 1.40 ± 0.65 <0.0001
Extended Friedewald approach (eFW)c
VLDL-TG (mmol/l) 1.36 ± 0.85 1.12 ± 0.79 0.95 ± 0.6 0.85 ± 0. <0.0001
IDL-C (mmol/l) 0.38 ± 0.14 0.28 ± 0.11 0.23 ± 0.11 0.23 ± 0.16 <0.0001
LDL-C (mmol/l) 3.55 ± 0.78 3.01 ± 0.71 2.49 ± 0.63 2.21 ± 0.51 <0.0001
HDL-2-C (mmol/l) 0.57 ± 0.23 0.67 ± 0.27 0.76 ± 0.27 0.77 ± 0.28 <0.0001
HDL-3-C (mmol/l) 0.46 ± 0.07 0.47 ± 0.07 0.48 ± 0.07 0.48 ± 0.07 0.0121
ApoA1 (g/l) 1.38 ± 0.22 1.38 ± 0.24 1.42 ± 0.24 1.37 ± 0.26 0.1864
ApoB (g/l) 1.30 ± 0.26 1.09 ± 0.26 0.90 ± 0.23 0.81 ± 0.18 <0.0001
Mean ± standard deviation are presented
Abbreviations: DSDI daily statin dose index, where the 1.0 corresponds the dose of simvastatin 20 mg per day (see Methods). In the intention to threat analysis all
patients are included
aANOVA was used for overall analysis
bLDL-C is determined using Friedewald calculation
cThe eFW is based on artificial neural network regression algorithms which utilize data on classical FW inputs (see Methods)
Fig. 2 a Apolipoprotein B (ApoB, g/l), VLDL-triglycerides (mmol/l)
and IDL-cholesterol (mmol/l) at postoperative visits. b Apolipoprotein
A-1 (ApoA1, g/l), HDL-cholesterol (mmol/l), HDL2-cholesterol (mmol/l)
and HDL3-cholesterol (mmol/l) at postoperative visits are shown both
as curves and as linear representations. All parameters except HDL-C
were obtained using extended Friedewald approach
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guideline recommendations [33]. However, our results
reveal that, in a proactive clinic, it is feasible to react with-
out delay to the inflowing relevant information describing
results of new well-conducted lipid-lowering trials pub-
lished in peer-reviewed high-impact journals.
The concentrations of HDL-C and phospholipids, as
well as the HDL2/HDL3-ratio, increased in the CABG
patients during the 20-year observational period. Re-
garding the potential clinical significance of these obser-
vations, following points need to be considered. The
apparently beneficial changes must have been partly due
to statin treatment and partly to life style changes. Inas-
much as beneficial life style changes are accompanied by
beneficial changes in various cardiometabolic measures,
quantitation of the role of changes in Apolipoprotein A-
I containing lipoproteins or their components is not
feasible. Similarly, the clinical relevance of the minor
statin induced increases in various parameters of HDL
particles and their constituents remains uncertain. Inter-
estingly, the moderate increase in HDL-C levels with
statins correlates with regression of coronary athero-
sclerosis [34]. With respect to the size of the HDL parti-
cles, the larger HDL2 particles have been associated with
greater CHD protection than the smaller HDL3 particles
[35, 36]. However in recent meta-analysis of 80 pub-
lished investigations, no differences in cardioprotective
properties between these two HDL subclasses were dis-
cerned [37, 38]. Importantly, regarding the cardioprotec-
tive functions of HDL, the scientific interest is shifting
largely to unravelling the biologic activity of HDL [38].
Thus, assigning any presumed clinical significance to the
modest increases in the various metrics of Apo A-I con-
taining lipoprotein fractions is not possible at present.
Although LDL is considered the main atherogenic
cholesterol-rich particle, also other apoB-containing li-
poproteins contribute to intimal cholesterol deposition,
i.e. they also are atherogenic [20]. Importantly, the re-
cent increase in the incidence of metabolic syndrome
and diabetes has re-emphasized the requirement for
obtaining additional data on triglyceride rich lipopro-
teins like VLDL and IDL. For example, IDL particles and
their cholesterol are contributing to the progression of
coronary and carotid artery atherosclerosis [39]. Besides
the number of apoB-containing lipoproteins, also the
size of these particles is considered a key determinant in
atherosclerosis [40]. The small dense LDL particles,
when being present in high numbers, particularly in-
crease the risk of ischemic heart disease [41]. While the
large chylomicrons fail to penetrate the arterial wall,
triglyceride rich chylomicron remnants and VLDL rem-
nants (IDL) with smaller particle sizes, enter the arterial
wall and so drive atherogenesis [20, 42, 43]. To the best
of our knowledge, an observation of diminished IDL-C
during intensified statin treatment with lipid values taken
and analysed 1–3 months postoperatively over a time span
of 20 years, has not been reported earlier.
A limitation associated with this study is its retrospect-
ive nature. Therefore we lack knowledge of possible sta-
tin intolerance, which is nowadays considered a notable
problem in statin treatment. Although in observational
studies even 10–15 % of patients have reported muscle
symptoms, most of them might be successfully treated
with careful management [44, 45]. During the last years
of our study only about 2 % of patients were not on sta-
tins. That might represent the maximal percentage of
patients suffering from clinically relevant statin intoler-
ance in this well-motivated patient population. A pos-
sible explanation for the success in statin therapy might
be the highly individualized care of the cardiovascular
patients in our hospital.
Due to the retrospective nature of this study, the
investigators had to rely on medical records with all
their imperfections. For example, information concern-
ing laboratory values and medications was occasionally
incomplete. Nevertheless, for 85 % of the patients all
relevant data were available. Moreover, during the last
four decades our hospital has had a fairly stable catchment
population without any significant national or international
migration. Thus the genetic and racial backgrounds, two
factors of potential importance considering the limited size
of our study sample, have remained stable.
Conclusions
To conclude, prominent increase of statin use in patients
undergone CABG took place immediately after the first
statin mega-trial was published. Further, over a 20-year
period (1990–2009) the efficacy of statin treatment grad-
ually increased and the concentration of LDL-C, measured
1–3 months postoperatively, gradually decreased. Also the
decreases of apoB, IDL-C and VLDL-TG were favourable.
Our results show that, based on the outcomes of relevant
mega-trials, it is possible in a single centre to optimise clin-
ical practice without delay even before they have led to
reformulations of international guidelines.
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